TherapeuticsMD (NYSE: TXMD) reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.93 million versus the consensus estimate of $5.73 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.